tetano
Editor, Senior Moderator
Antiviral Res. 2017 Sep 22;146:213-220. doi: 10.1016/j.antiviral.2017.09.014. [Epub ahead of print]
[h=1]Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.[/h] Chen TH[SUP]1[/SUP], Liu YY[SUP]1[/SUP], Jan JT[SUP]2[/SUP], Huang MH[SUP]3[/SUP], Spearman M[SUP]4[/SUP], Butler M[SUP]4[/SUP], Wu SC[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Humans infected with H7N9 avian influenza viruses can result in severe pneumonia and acute respiratory syndrome with an approximately 40% mortality rate, and there is an urgent need to develop an effective vaccine to reduce its pandemic potential. In this study, we used a novel PELC/CpG adjuvant for recombinant H7HA (rH7HA) subunit vaccine development. After immunizing BALB/c mice intramuscularly, rH7HA proteins formulated in this adjuvant instead of an alum adjuvant elicited higher IgG, hemagglutination-inhibition, and virus neutralizing antibodies in sera; induced higher numbers of H7HA-specific IFN-γ-secreting T cells and antibody secreting cells in spleen; and provided improved protection against live virus challenges. Our results indicate that rH7HA proteins formulated in PELC/CpG adjuvant can induce potent anti-H7N9 immunity that may provide useful information for H7N9 subunit vaccine development.
Copyright ? 2017 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; H7N9; PELC/CpG; Subunit vaccine
PMID: 28947234 DOI: 10.1016/j.antiviral.2017.09.014
[h=1]Recombinant hemagglutinin proteins formulated in a novel PELC/CpG adjuvant for H7N9 subunit vaccine development.[/h] Chen TH[SUP]1[/SUP], Liu YY[SUP]1[/SUP], Jan JT[SUP]2[/SUP], Huang MH[SUP]3[/SUP], Spearman M[SUP]4[/SUP], Butler M[SUP]4[/SUP], Wu SC[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Humans infected with H7N9 avian influenza viruses can result in severe pneumonia and acute respiratory syndrome with an approximately 40% mortality rate, and there is an urgent need to develop an effective vaccine to reduce its pandemic potential. In this study, we used a novel PELC/CpG adjuvant for recombinant H7HA (rH7HA) subunit vaccine development. After immunizing BALB/c mice intramuscularly, rH7HA proteins formulated in this adjuvant instead of an alum adjuvant elicited higher IgG, hemagglutination-inhibition, and virus neutralizing antibodies in sera; induced higher numbers of H7HA-specific IFN-γ-secreting T cells and antibody secreting cells in spleen; and provided improved protection against live virus challenges. Our results indicate that rH7HA proteins formulated in PELC/CpG adjuvant can induce potent anti-H7N9 immunity that may provide useful information for H7N9 subunit vaccine development.
Copyright ? 2017 Elsevier B.V. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; H7N9; PELC/CpG; Subunit vaccine
PMID: 28947234 DOI: 10.1016/j.antiviral.2017.09.014